APOE and Alzheimer disease: The finding of cortical thickening in AD vulnerable areas in middle aged (48–75 years old) APOE4 carriers with respect to non-carriers has already been described [16], [17], but it is in contrast with other works assessing older cohorts [3], [4], [14], [15].